ResearcherArmy Medical UniversityNo recent work listed

H Wang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5006758251. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2016: 1 paper

Papers 1

Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Last author DOI 10.1038/onc.2016.90 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

J Li · 1 shared paper, 2016 · strength 0.05
- Paper Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB sign… DOI 10.1038/onc.2016.90 ↗
Yongsheng Ouyang · 1 shared paper, 2016 · strength 0.05
- Paper Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB sign… DOI 10.1038/onc.2016.90 ↗
Bing Ni · 1 shared paper, 2016 · strength 0.05
- Paper Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB sign… DOI 10.1038/onc.2016.90 ↗
Zhiping Zhao · 1 shared paper, 2016 · strength 0.05
- Paper Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB sign… DOI 10.1038/onc.2016.90 ↗
Shixiang Guo · 1 shared paper, 2016 · strength 0.05
- Paper Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB sign… DOI 10.1038/onc.2016.90 ↗
Heshui Wu · 1 shared paper, 2016 · strength 0.05
- Paper Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB sign… DOI 10.1038/onc.2016.90 ↗
Jingfang Ju · 1 shared paper, 2016 · strength 0.05
- Paper Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB sign… DOI 10.1038/onc.2016.90 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.